Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + CAPOX in unresectable/recurrent or metastatic ampullary tumors
ChiCTR2200061710Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in Ampullary cancer (AC), duodenal papillary cancer and Distal Common Bile Duct Carcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: progression-free survival. Started Nov 2022; status: recruiting.
02
Drugs
surufatinib
03
Conditions
Ampullary cancer (AC)duodenal papillary cancerDistal Common Bile Duct Carcinoma
Beyond the preview
Go deeper on ChiCTR2200061710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061710.